The QualityStocks Daily Thursday, March 19th, 2020

Today's Top 3 Investment Newsletters

StockMarketWatch (CEFZ) +146.32%

StreetInsider (GES) +124.49%

MarketClub Analysis (CXRXF) +107.31%

The QualityStocks Daily Stock List

Body and Mind, Inc. (BMMJ)

OTC.Watch, Penny Stock Tweets, Business Insider, Insider Financial, Market News Updates, New Cannabis Ventures, Midas Letter, GlobeNewswire, Dividend Investor, Wallmine, PotStockNews, technical420, Dividend.com, Investor Ideas, Stockhouse, MicroSmallCap, Wallet Investor, GuruFocus, Trading View, Simply Wall St, InvestorsHub and YCharts reported beforehand on Body and Mind, Inc. (BMMJ), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Body and Mind, Inc. invests in high quality medical and recreational cannabis cultivation, production and retail. The Company’s wholly-owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licences. Furthermore, Body and Mind holds cultivation and production licenses. Body and Mind (BaM) products include dried flower, edibles, topicals, extracts, and GPEN Gio cartridges. Body and Mind is headquartered in Vancouver, British Columbia. Nevada Medical Group LLC (NMG Nevada) is a wholly-owned subsidiary of the Company. Body and Mind’s shares trade on the OTC Markets Group’s OTCQB.

Body and Mind has collected, for many years’, elite cannabis plants from around the world. Through carefully crossbreeding these plants, it has developed strains that give what it states are the perfect balance of body and mind benefits. Its cannabis plants are grown with hands-on care in small batches. In addition, Body and Mind never uses synthetic pesticides.

The Company offers an assortment of strains, available in flower, vapes, pre-rolls and concentrates. Body and Mind cannabis strains have won manifold awards including the 2019 Las Vegas Weekly Bud Bracket, Las Vegas Hempfest Cup 2016, High Times Top Ten, the NorCal Secret Cup and the Emerald Cup.

Body and Mind has commenced manufacturing in the State of California through the Body and Mind California subsidiary NMG Cathedral City (NMG). Since June of 2018, the Cathedral City facility has been producing THC (Tetrahydrocannabinol) distillate in bulk form. This facility is for manufacturing popular Body and Mind products. This includes oils, wax, live resin, ambrosia, and edibles. Body and Mind continues to expand operations in the States of Nevada, California, Arkansas and Ohio.

Last month, Body and Mind announced that it received all required permits to begin operations at its new Nevada production facility located within one mile of the Pepper Lane cultivation facility. The new production facility will be located within a 7,500 square foot commercial building where Body and Mind has secured a long-term lease. Equipment was being moved into the facility; the space has been custom designed to produce edibles, oils and extracts at scale. With the increased production capacity, Body and Mind plans to offer contract manufacturing for other brands of complementary products.

In early March, Body and Mind updated shareholders on its progress in San Diego and Arkansas and also other corporate matters. It has substantially completed construction at the San Diego dispensary located in Miramar, San Diego. Hiring is complete with training underway and Body and Mind has started ordering inventory.

In Arkansas, construction of the dispensary is progressing well. Interior and exterior work, including millwork installation and landscaping, is substantially complete. Moreover, Mr. Trip Hoffman has been appointed to the Board of Directors of Body and Mind. At present, Mr. Hoffman is the Chief Operating Officer of Body and Mind, was the past co-owner of a Colorado licensed marijuana cultivation facility, and was previously the Chief Executive Officer of a Colorado licensed cultivation and dispensary company.

Body and Mind, Inc. (BMMJ), closed Thursday's trading session at $0.2406, up 41.6961%, on 110,230 volume with 78 trades. The average volume for the last 3 months is 72,445 and the stock's 52-week low/high is $0.153799995/$2.70000004.

chart

Coral Gold Resources Ltd. (CLHRF)

Northern Miner, Resource World, Mining Capital, Junior Mining Network, Investors Hub, Baystreet.ca, Stockwatch, 24hgold, TMX Matrix, Morningstar, Big News Network, Investing News, Mining Stock Valuator, GlobeNewswire, Mining Stock Education, Dividend.com, Accesswire, Barchart, Business Insider, Canadian Mining Report, The National Investor, Nasdaq, TradingView, Market Screener, Dividend Investor, TMXmoney, OTC Markets, Central Charts, FSC Wire, Barron’s, Ceo.ca, Stockhouse, Seeking Alpha, Wallet Investor, Street Insider, and PR Newswire reported earlier on Coral Gold Resources Ltd. (CLHRF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Coral Gold Resources Ltd. is a precious metals exploration company operating in the State of Nevada. Its chief asset is a sliding scale net smelter returns (NSR) production royalty on Nevada Gold Mines' Robertson Property in Nevada. The Company previously went by the name Coral Gold Corp. It changed its name to Coral Gold Resources Ltd. in September of 2004. Coral Gold Resources’ shares trade on the OTC Markets Group’s OTCQX. The Company is based in Vancouver, British Columbia.

Coral Gold Resources also holds a portfolio of strategically-located exploration projects near Nevada Gold Mine's Pipeline/Cortez Mine Complex on Nevada's Battle Mountain/Cortez Trend. Coral Gold Resources remains debt free with a strong balance sheet.

The 2017 sale of Robertson to Barrick Gold (now Nevada Gold Mines, or NGM) included a sliding scale 1 percent to 2.25 percent NSR royalty, payable quarterly, subject to potential advance royalty payments, and a right of first refusal enabling NGM to acquire the NSR in the event that the Company wishes to sell the NSR to any third party. The royalty increases with increases in the price of gold.

Coral Gold Resources also has its JDN Property. The JDN Property is 27 claims (560 acres) 10 miles NNW of Gold Acres and Pipeline Gold Mines. It adjoins the Cortez Hilltop deposit - indicated resource 700,000 oz Au. The Company also has its Norma Sass Property. This is an early exploration-stage project positioned immediately south of the Gold Acres open pit mine and west of the Pipeline open pit mine. It represents a major exploration target and prior drilling at Norma Sass encountered gold hosted by favorable, lower-plate carbonate strata.

Moreover, Coral Gold Resources has its Eagle Property. This property is situated just south of Hecla’s Fire Creek Mine. A total of 28 holes drilled in two campaigns hit manifold intersections of anomalous gold and drilling depths ranged from 120’ to 700’.

This week, Coral Gold Resources reported that Nevada Gold Mines (NGM) continues to advance activities on the Robertson Project in the Cortez region of Nevada where Coral Gold Resources retains a net smelter returns royalty (NSR). Recently, NGM delivered its summary of work completed in Q4 2019 at Robertson, reporting that 1,675 meters of geotechnical drilling was completed. NGM is progressing with updating the geological model, preparing mine plans, confirming metallurgical assumptions, and carrying out baseline study work.

Coral Gold Resources Ltd. (CLHRF), closed Wednesday's trading session at $0.195, up 14.3695%, on 153,727 volume with 208 trades. The average volume for the last 3 months is 116,945 and the stock's 52-week low/high is $0.14/$1.32000005.

chart

Cryo-Cell International, Inc. (CCEL)

Whale Wisdom, Zacks, Equities.com, GuruFocus, Stockhouse, YCharts, Nasdaq, Proactive Investors, Morningstar, TMXmoney, Market Screener, last10k, CSI Market, Barchart, GlobeNewswire, Simply Wall St, Seeking Alpha and InvestorsHub reported earlier on Cryo-Cell International, Inc. (CCEL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets, Cryo-Cell International, Inc. is the world’s first private cord blood bank. The Company’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services, raise awareness of the opportunity for expectant parents to bank or donate their baby’s cord blood, and support the advancement of regenerative medicine. Cryo-Cell markets its cord blood stem cell preservation services directly to expectant parents, and by distributing information via obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Established in 1989, Cryo-Cell International has its corporate office in Oldsmar, Florida.

Greater than 500,000 parents from 87 countries have entrusted the Company with their baby’s cord blood and cord tissue stem cells. Further to its family bank, Cryo-Cell International has a public banking program in partnership with Duke University. The Company’s public bank has provided cord blood for over 600 transplantations. It operates cord blood donation sites throughout the United States in well-known hospitals including Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami.

Cryo-Cell International operates in a facility that is FDA (Food and Drug Administration) registered, cGMP-/cGTP-compliant and licensed in all States requiring licensure. The Company is AABB accredited as a cord blood facility.

In addition, Cryo-Cell International was the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any globally recognized, independent accrediting organization. The Company is also ISO 13485:2003–certified by TÜV, an internationally recognized, quality assessment organization.

Cryo-Cell International holds an interest in more cord blood patents than any other cord blood bank by way of its equity position in Saneron CCEL Therapeutics, a University of South Florida spin-out biotechnology company. Saneron’s dedication is to advancing research using readily available, non-controversial cord blood stem cells. Saneron’s research emphasis is to actively seek new cellular therapy discoveries for treatment of and intervention in devastating, life-threatening illness and conditions including heart attack, Alzheimer’s disease, stroke, and spinal cord injury.

Recently, Cryo-Cell International announced results for its Fiscal Year ended November 30, 2019. Consolidated Revenues for Fiscal 2019 were $31.8 million versus $29.2 million for fiscal 2018. Cryo-Cell reported Net Income of $2.3 million in Fiscal 2019 or $0.29 per basic and $0.27 per diluted share, versus a Net Loss of ($855,000) in Fiscal 2018 or ($0.11) per basic and diluted shares.

Cryo-Cell International, Inc. (CCEL), closed Thursday's trading session at $6.44, up 17.0909%, on 1,120 volume with 5 trades. The average volume for the last 3 months is 2,040 and the stock's 52-week low/high is $5.0999999/$8.89999961.

chart

GrainCorp Limited (GRCLF)

Speculating Stocks, Stock Target Advisor, Grain Central, ValueWalk, ETF Daily News, OTC Markets, Street Insider, Stockscores, TipRanks, Dividend Investor, Wallet Investor, YCharts, Seeking Alpha, Nasdaq, GuruFocus, Wallmine, Morningstar, Barchart, Dividend.com, Capital Cube, TradingView, moneyhub.net, Market Screener, 4-Traders and StockInvest.us reported earlier on GrainCorp Limited (GRCLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

GrainCorp Limited is a foremost global agribusiness based in Sydney, Australia. The Company has diversified operations that span four continents and supplies customers in more than 30 countries. It operates a unique mix of interlinked businesses – Grains, Malt and Oils. GrainCorp centers its activities on three core grains (wheat, barley and canola) where it has comparative advantages through grain origination, freight differentials, as well as technical expertise. Established in 1916, and incorporated in 1989, the Company lists on the OTC Markets.

GrainCorp has operations in Australia, New Zealand, North America, Europe, and the United Kingdom. These operations collectively represent greater than 50 percent of international export trade in wheat, barley and canola.

GrainCorp has the largest Eastern Australian grain storage and transport network. It has seven bulk grain ports and is a Top 4 global commercial maltster. It is Australia’s largest integrated edible oils business and its GRAINSCONNECT CANADA Joint Venture (JV) is a game-changing supply chain in Western Canada.

The Company’s fully integrated operations begin in regional communities with a broad network of storage and accumulation sites, seamlessly linked to rail and road freight options. GrainCorp’s port facilities ensure quick turnaround to provide a quality assured product worldwide.

The Company owns the largest network of regional storage sites in eastern Australia – with a total storage capacity of more than 20 million tonnes (mmt). This is supported by an annual rail capacity surpassing 4 million tonnes, linked to the Company’s seven bulk export terminals.

GrainCorp Malt is one of the world’s top four commercial maltsters with an international footprint spanning four countries (Canada, UK, USA and Australia). It supplies a broad range of malts to greater than 5,000 customers worldwide. This includes some of the world’s foremost brewers.

GrainCorp Oils is the largest processor of high quality edible oils in Australia and New Zealand. It produces a wide spectrum of quality food ingredients from premium oils and blends, to infant formula nutrition products.

GrainCorp has 100-plus active buyers purchasing grain in its network. More than 20 grain exporters access the Company’s ports. GrainCorp has a malting capacity of 1.25 million tonnes annually. In addition, the Company has 300,000MT oilseed crushing capacity and 300,000MT oil refining capacity annually.

GrainCorp Limited (GRCLF), closed Thursday's trading session at $4.03, up 0.75%, on 1,550 volume with 4 trades. The average volume for the last 3 months is 2,936 and the stock's 52-week low/high is $4.00/$6.8499999.

chart

Peeks Social Ltd. (PKSLF)

Capital Cube, Stock Pulse, Stockwatch, Stockhouse, GlobeNewswire, StockInvest.us, Stock Day Media, Cantech Letter, InvestorX, TeleTrader, GuruFocus, OTC Markets, Market Screener, Global Banking and Finance, Mobile Marketer, Wallet Investor, TradingView, Seeking Alpha, TMXmoney, Nasdaq, MarketWatch, InvestorsHub, Simply Wall St and Dividend.com reported beforehand on Peeks Social Ltd. (PKSLF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Peeks Social Ltd. engages in the development and marketing of mobile video and livestreaming social media products. The Company does so under the Peeks Social brand for consumers and businesses in Canada. Peeks Social is based in Toronto, Ontario. It operates in Canada, the United States, Africa, the Middle East, India, Europe, and internationally. The Company lists on the OTC Markets Group’s OTCQB.

Peeks Social is a live streaming platform. A user can ‘go live’ and begin broadcasting their stream from anywhere to anyone globally. A user can grow their followers overnight by getting featured in Peeks Social. Furthermore, they can explore by watching exclusive live streams and videos from around the world and also receive special offers.

A user can become a broadcaster through downloading the Peeks Social App and start broadcasting. They can become a Peeks Social Influencer. One can join the Peeks Social Influencer program and increase their star power. Additionally, they can get special deals and earn more coins.

A user can also earn money with Peeks Social through getting sponsored. A user can get automatically paired with an advertising partner based on the keywords in their stream title and earn money for each interaction.

In February, Peeks Social announced that further to its press release dated February 13, 2020, there was an error in the number of units being issued to Mr. Mark Itwaru, Chief Executive Officer of the Company. The number was reported as 41,141,340 and should have been 39,141,340.

On February 13, 2020, it was announced that an additional $310,000 of financing had been further arranged to the Company’s January 13, 2020 announcement pertaining to a non-brokered private placement. Management and Insiders have subscribed for $300,000 of the total amount of this second $310,000 tranche.

$200,000 of the final tranche was being contributed by Chief Marketing Officer Mr. Rick Padulo and an additional $100,000 from Mr. Itwaru was contributed on top of Mr. Itwaru’s earlier announced $1,857,067 from January 13, 2020 for a total of $1,957,067. In total, Peeks Social issued an aggregate of 39,141,340 units at a price of $0.05 per units to Mark Itwaru, for gross proceeds of $1,957,067. The private placement proceeds will be used for ongoing for general corporate purposes.

Peeks Social Ltd. (PKSLF), closed Thursday's trading session at $0.0171, even for the day, on 16,750 volume. The average volume for the last 3 months is 5,947 and the stock's 52-week low/high is $0.0031/$0.090899996.

chart

Stereotaxis, Inc. (STXS)

NetworkNewsWire, Investors Observer, Stock Twits, Zacks, Insider Tracking, Proactive Investors, YCharts, Earnings Cast, Market Screener, Stockopedia, Simply Wall St, Equity Clock, GuruFocus, MarketWatch, Insider Financial, CSI Market, Investchronicle.com, Wallet Investor, InvestorsHub, Stockhouse, Equities, 4-Traders, Barchart and Dividend Investor reported previously on Stereotaxis, Inc. (STXS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Stereotaxis, Inc. is the international leader in inventive robotic technologies for the treatment of cardiac arrhythmias. The design of these robotic technologies are to enhance the treatment of arrhythmias and perform endovascular procedures. Greater than 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, Canada, the European Union (EU), Japan, China, and elsewhere. Stereotaxis is headquartered in St. Louis, Missouri.

The Company’s mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide premier patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ core Epoch™ Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive™ robotic navigation system and consumables.

Stereotaxis provides increased efficacy and efficiency in combination with a first-in-class safety profile in ventricular arrhythmias, congenital procedures, and certain other special situations. The validation of the value provided in these procedures is in the fact that many leading hospitals have adopted Stereotaxis for all of their ventricular procedures and have seen considerable growth following adoption of the technology.

Earlier this month, Stereotaxis announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® System for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders. The Genesis RMN System builds upon the established benefits and reliability of RMN in a unique architecture that is quicker, smaller, lighter and more flexible. It uses smaller magnets rotated along their center-of-mass for increased speed and control. Across a wide range of navigational routines, the Genesis System is 70 percent to 80 percent faster than its predecessor.

Mr. David Fischel, Stereotaxis Chairman and Chief Executive Officer, said, “Genesis is a leap forward in Robotic Magnetic Navigation technology. We are confident Genesis will have a meaningful impact on patients, physicians, and providers in Electrophysiology. Genesis is a reflection of our commitment to positively transform interventional medicine with robotics.”

In 2019, Stereotaxis launched the Genesis RMN System, a highly innovative next-generation robotic system, along with Stereotaxis Imaging Model S, a tightly-integrated x-ray solution developed in collaboration with Omega Medical. In addition, Stereotaxis entered into a strategic collaboration with Osypka AG to develop a proprietary robotically-navigated magnetic ablation catheter and to support a long-term broad collaboration in electrophysiology.

Stereotaxis, Inc. (STXS), closed Thursday's trading session at $2.08, up 17.5141%, on 389,250 volume with 1,918 trades. The average volume for the last 3 months is 328,501 and the stock's 52-week low/high is $1.67999994/$5.82000017.

chart

TearLab Corporation (TEAR)

Zacks, Proactive Investors, MacroTrends, Wallet Investor, TipRanks, Morningstar, BioSpace, Simply Wall St, MarketBeat, Nasdaq, Market Screener, GlobeNewswire, P&T Community, Stockhouse, Investing.com, TMXmoney, Simply Wall St, Barchart and StockInvest.us reported beforehand on TearLab Corporation (TEAR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TearLab Corporation develops and markets lab-on-a-chip technologies. These technologies enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The Company’s mission is to pioneer the future of tear film diagnostics to elevate patient care. TearLab has its head office in Escondido, California. The Company lists on the OTC Markets’ OTCQB.

The TearLab Osmolarity Test is for diagnosing Dry Eye Disease. It is the first assay developed for the award-winning TearLab Osmolarity System. The TearLab Osmolarity System is a proprietary in vitro diagnostic tear testing platform. It measures tear film osmolarity for the diagnosis of dry eye disease. Furthermore, it enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.

The Company’s TearLab Osmolarity System comprises TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, and also provides a quantitative reading for the operator. TearLab is for professional in vitro diagnostic use only.

Earlier this month, TearLab reported its consolidated financial results for Q4 and twelve months ended December 31, 2019. For the three months ended December 31, 2019, the Company’s Net Revenues were $5.5 million, down 8.3 percent from $6.0 million for the same period in 2018. TearLab’s reported Net Loss for the 2019 Q4 was roughly $1.2 million, or ($0.09) basic loss per share, versus a reported Net Loss of roughly $0.5 million, or ($0.05) basic loss per share in Q4 of 2018.

Seph Jensen, TearLab’s Chief Executive Officer, said, “We were pleased to continue the expansion of our customer base throughout 2019. We remain focused on the resubmission of our 510(k) application to secure FDA clearance of our next-generation TearLab Discovery™ System.”

TearLab Corporation (TEAR), closed Thursday's trading session at $0.038, up 39.5776%, on 70,488 volume with 9 trades. The average volume for the last 3 months is 35,188 and the stock's 52-week low/high is $0.025/$0.115000002.

chart

Iconic Brands, Inc. (ICNB)

Stock News Union, Discovery Stocks, Insider Financial, Stockhouse, Barchart, InvestorsHub, Wallmine, 4-Traders, Wallet Investor, OTC Markets, GuruFocus, Marketwired, Street Insider, YCharts, Last10k, Trading View, Investors Hangout, Business Wire, Emerging Growth, Stockopedia, Stockwatch, and Simply Wall St reported earlier on Iconic Brands, Inc. (ICNB), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Iconic Brands, Inc. is a beverage company listed on the OTC Markets Group’s OTCQB. The Company’s expertise is developing, from inception to completion, alcoholic beverages for itself and third parties. It markets and places products into national distribution via long standing industry relationships. Iconic Brands offers wine and distilled alcoholic beverages, and also liquor based products infused with hemp and CBD. The Company is headquartered in Amityville, New York.

Iconic Brands is a leader in Celebrity and Private Label beverages. It obtains first-rate and innovative products from around the world and brands its products with globally recognized celebrities and corporate icons. The Company’s corporate mission is to be the industry leader in brand development, marketing, and sales of the highest quality alcoholic beverages.

Iconic Brands is under contract with United Spirits - a federally-licensed importer and distributor of alcoholic beverages. In addition, the Company is under contract with Mr. Dan Kay, who maintains a New York State warehousing license for alcoholic beverages.

Regarding Services, Iconic Brands’ takes a customer’s product idea from concept to completion. This includes everything from sourcing, flavor profiles, packaging, design, marketing and distribution. Iconic an also align a customer’s brand with select celebrity endorsement. Iconic markets its products under the Bivi, Bellissima, Bella, and Romano brand names.

In March, Iconic Brands announced it entered into a Letter of Intent (LOI) to acquire recently formed Green Grow Farms, Inc. Green Grow Farms partners directly with farmers to transition their crops to hemp for the purpose of extracting Cannabidiol (CBD Isolate/Oil). It provides full support services and logistics to take product from seed to sale.

Iconic Brands previously announced that Green Grow Farms secured a processor and material supplier agreement with one of the largest vertical Hemp processors in the world. The agreement is for an initial 2-year term. It allows for a minimum of 2 million pounds of biomass to be processed to CBD isolate, and sold under a revenue sharing agreement. With average CBD percentage and processing efficiency rates from Green Grow’s farming operations, two million pounds should process into roughly 40,000 kilograms of CBD Isolate.

Recently, Iconic Brands, in conjunction with its Licensed Partner, United Spirits, announced the introduction of Hooters Spirits, with the official debut at this year’s WSWA Conference. Hooters Spirits is a private label brand for Hooters of America, the iconic restaurant chain. The product portfolio comprises Hooters Vodka, Hooters Gin, Hooters Rum, Hooters Tequila, Hooters American Whiskey and Hooters Shooter, a cinnamon flavored whiskey.

Iconic Brands, Inc. (ICNB), closed Thursday's trading session at $0.49, up 104.2518%, on 117,193 volume with 56 trades. The average volume for the last 3 months is 63,687 and the stock's 52-week low/high is $0.200000002/$2.13849997.

chart

Technicolor SA (TCLRY)

Amigo Bulls, MarketWatch, The Street, Wallmine, Capital Cube, 4-Traders, Wallet Investor, Zacks, Seeking Alpha, GuruFocus, Market Screener, Marketbeat, Financial Content, Barchart, Morningstar, otc.watch, Last10k, Stockhouse, Trading View, Dividend Investor, and YCharts reported earlier on Technicolor SA (TCLRY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Technicolor SA provides diverse communication and video technologies, finished products, systems, equipment, and services for businesses and professionals in the entertainment and media industries globally. Its award-winning artists and technologists work with the creative community across film, television, gaming, and advertising to bring the universal art of storytelling to audiences globally. The Company is based in Issy-les-Moulineaux, France. Technicolor lists on the OTC Markets Group’s OTCQX.

The Company engineers next-generation home network and video solutions. These solutions allow bandwidth intensive content to be distributed at gigabit speeds and enjoyed seamlessly irrespective of place, device or time.

Technicolor operates via two segments - Entertainment Services and Connected Home. The Entertainment Services segment provides production services; visual effects and animation services for feature films, TV series, advertising, and video games; computer generated imagery animation services; on-set, color correction, VFX integration, and sound services. It also replicates, packages, and distributes video, game and music DVD, Blu-ray, and CD discs. Moreover, it offers turnkey integrated supply-chain solutions.

The Connected Home segment designs and supplies set-top boxes, broadband modems and gateways, and Internet of Things (IoT) connected devices. It also designs and supplies multi-device communication software, smart home applications, and related professional services.

In February, Technicolor announced it received a binding offer and entered into exclusive negotiations with InterDigital (IDCC) for the sale of its Research & Innovation activity. Of note is that InterDigital acquired Technicolor’s Patent Licensing business last year. InterDigital is a mobile technology research and development company.

Mr. Frederic Rose, Technicolor’s Chief Executive Officer, stated: "This proposed transaction continues the simplification of the Group’s structure while ensuring that its R&I teams join a world class technological organization. As a result, Technicolor will henceforth be able to focus its resources solely on its operating businesses."

Recently, Technicolor announced its results for the full year 2018. Revenues from Continuing Activities were €3,988 million, down 3 percent year-on-year at constant rate, with an Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of €266 million versus €341 million in 2017. Sales in the second half of the year increased by 3 percent at constant rate, boosted in particular by a strong 5 percent during the last quarter.

Technicolor has also increased its investments in organic growth in Production Services and in the transformation program in Connected Home. The expectation is that these initiatives will continue over the next few years in well-defined areas.

Technicolor SA (TCLRY), closed Thursday's trading session at $0.37, up 121.5569%, on 807 volume with 2 trades. The average volume for the last 3 months is 2,014 and the stock's 52-week low/high is $0.166999995/$1.467.

chart

Dream Homes & Development Corporation (DREM)

Stockhouse, InvestorsHub, Morningstar, TradingView, Digital Journal, YCharts, Wallet Investor, Wall Street Analyzer, Stockwolf, Wallstreet-Online, Penny Stock Hub, Stockwatch, Dividend Investor, Barchart, Simply Wall St. and Investors Hangout reported earlier on Dream Homes & Development Corporation (DREM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dream Homes & Development Corporation is a fully integrated real estate company listed on the OTC Markets’ OTCQB. Licensed new home builders and general contractors, Dream Homes is building, raising, renovating and reconstructing homes up and down the New Jersey shore area. Established in 2009, and a full-service construction company, Dream Homes & Development is based in Forked River, New Jersey.

Dream Homes & Development is equipped to complete all facets of a building project. This includes design, architectural, engineering, and construction. The Company is a full-service building and development enterprise that operates chiefly in the coastal areas of New Jersey.

Dream Homes & Development provides an array of services and products. These include land development and approvals, infrastructure installation, new single and multi-family construction, engineering & structural design, soil studies, architectural and design/build capabilities, and construction management services.

Services and products provided additionally include general contracting of all residential single and multi-family construction, helical and timber pile installation, masonry foundations and concrete work of all varieties, management of home elevation and moving projects and complete finish requirements for all interior construction.

Dream Homes has successfully completed over 1,500 new homes and more than 200 elevation projects. The Company is contracted to develop and construct a 60-unit town home development in Lacey Township, New Jersey over the next two years valued at $12 to $14 million.

At present, Dream Homes & Development has a number of new home properties under contract and in development. These new developments include 13 single family homes, 58 townhomes and 68 waterfront townhomes, all in the Ocean County region of New Jersey.

Dream Homes & Development has its new Modular Division in Point Pleasant, New Jersey. The office and showroom in Point Pleasant allows Dream Homes to better serve the northern Ocean/southern Monmouth region of New Jersey. It complements the main office in Forked River. The showroom offers a complete kitchen, bath, flooring, as well as finish design center. The new Design Center in Point Pleasant has led to growth in modular traffic and sales. In addition, it has facilitated and increased client selections throughout the Company’s entire region.

Dream Homes & Development has completed the acquisition of Premier Modular Homes. Premier has a 23-year record of accomplishment serving southern Ocean County with a focus on Long Beach Island. On October 20, 2018, Dream Homes acquired a substantial portion of the assets of Premier Modular Homes, located in Little Egg Harbor, New Jersey. The acquired assets include physical and intellectual property (IP), such as phone numbers, web site, use of the Premier Modular Home name, equipment, vehicles and trailers. Furthermore, the Company leased the physical premises. This includes the office, showroom, garage, as well as yard space.

Dream Homes & Development Corporation (DREM), closed Thursday's trading session at $0.04029, up 148.7037%, on 58,180 volume with 6 trades. The average volume for the last 3 months is 22,290 and the stock's 52-week low/high is $0.0161/$0.200000002.

chart

Towerstream Corp. (TWER)

MadPennyStocks, MarketClub Analysis, Money Morning, PennyOmega, OTCBB Journal, OTCMagic, Penny Picks, KingPennyStocks, BUYINS.NET, Damn Good Penny Picks, Penny Stock Prodigy, CoolPennyStocks, Epic Stock Picks, Hit and Run Candle Sticks, HotOTC, Investing Futures, MicroCapDaily, Investment Contrarians, Jason Bond, Broad Street, BullRally, PennyInvest, and ChartPoppers reported on Towerstream Corp. (TWER), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Towerstream Corp. is a leading Fixed-Wireless Fiber Alternative business.  The Company delivers high-speed Internet access to businesses. Together with its subsidiaries, it provides fixed wireless broadband services and delivers access over a wireless network transmitting over regulated and unregulated radio spectrum to commercial customers in the United States. Towerstream has its corporate office in Middletown, Rhode Island.

Towerstream announced earlier in 2018 that its Board of Directors started evaluation of strategic repositioning of the Company as it moves to take advantage of its existing important assets in major American markets. In association with the announcement, Towerstream launched a determined focus on indirect and wholesale channels and the retention of Bank Street Group LLC as its independent financial advisor to explore strategic alternatives with such broadband carriers.

Towerstream provides broadband services in twelve urban markets. These include New York City, Boston, Los Angeles, Chicago, Philadelphia, the San Francisco Bay area, Miami, Seattle, Dallas-Fort Worth, Houston, Las Vegas-Reno, and the greater Providence area.  Towerstream has constructed 175 Major Points of Presence (POPs). The Company positions its POPs on the tops of buildings.

Towerstream is a last-mile facilities-based provider. It owns its entire network. The Company totally bypasses the local exchange carrier and cable providers. Its solution to businesses either complements or replaces existing Internet connections. Towerstream provides property managers, building owners, and their commercial tenants a redundant and reliable dense urban network. This network directly connects to the Company’s fiber backbone. 

Towerstream has its Single Tenant Internet Solution. This solution is for customers not in On-Net buildings. The Single Tenant Internet Solution provides primary and back-up dedicated internet access as a faster and less expensive alternative to fiber. On-Net refers to the extensive number of buildings in Towerstream’s 12 coverage markets now lit for On-Net Business Internet Service. The Company’s On-Net Service provides businesses within its continually growing portfolio of On-Net buildings with dedicated and symmetrical Internet connectivity.

Towerstream Fixed Wireless features fast installation, guaranteed 99.99 percent uptime backed by the Company’s industry leading SLA, and scalability. It also features faster than fiber, true redundancy, and symmetrical speeds.

Towerstream Corp. (TWER), closed Thursday's trading session at $0.36, up 80.00%, on 2,087 volume with 11 trades. The average volume for the last 3 months is 419 and the stock's 52-week low/high is $0.200000002/$1.10000002.

chart

Regen BioPharma, Inc. (RGBP)

Small Cap Solutions, InvestorTrendz, Insider Financial, TopPennyStockMovers, YCharts, ProTrader, Emerging Growth, SmallCapVoice, Wall Street Mover, TheMicrocapNews, and The OTC Reporter reported earlier on Regen BioPharma, Inc. (RGBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter. 

Regen BioPharma, Inc. is a biotechnology company listed on the OTC Markets’ OTCQB. The Company works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. Its aim is to quickly advance these technologies through pre-clinical and Phase I/II clinical trials.  Checkpoint Immunology, Inc. is a wholly-owned subsidiary of the Company. Regen BioPharma has its head office in La Mesa, California.

At present, Regen BioPharma is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer. Furthermore, it is focusing  on developing stem cell treatments for aplastic anemia. Fundamentally, the Company is working to increase the quality of life through therapies involving small molecules, stem cell treatments, and the body's own immune system.  It is currently developing products treating blood disorders employing small molecules and gene silencing (DiffronC) and treating cancer with immunotherapy (dCellVax).

Regen BioPharma is also modulating vital molecular processes in cancer stem cells by way of its patented molecular targeting approaches (BORIS). In addition, it is repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). 

Regen BioPharma is centering on small molecules to activate and inhibit its main target of interest, NR2F6. The Company is continuing to develop the NR2F6 program in-house before entering into any potential partnerships. It has granted CheckPoint Immunology an exclusive international license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen BioPharma’s small molecule technology from its other Intellectual Property (IP) to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.

In September, Regen BioPharma reported that its researchers identified a series of small molecule drugs, which inhibit NR2F6 as well as activate human immune cells ex-vivo. Evidence provided by studies suggest that NR2F6 represses the body's immune response against tumors. Therefore, inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor cells.

Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, said, "Based on the known activities of NR2F6, we expect that inhibiting its activity will lead to increased T cell activation. We found that several of our NR2F6 antagonists can activate human immune cells, such as T cells, leading to increased IL-17a production in a concentration-dependent manner."

Recently, Regen BioPharma reported that its researchers determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). Regen will pursue this testing as a joint venture (JV) with Zander Therapeutics, Inc. Zander Therapeutics has been granted an exclusive license by Regen to develop and commercialize the Company's NR2F6 IP for veterinary applications.

Regen BioPharma, Inc. (RGBP), closed Thursday's trading session at $0.0001, up 233.3333%, on 2,294,200 volume with 20 trades. The average volume for the last 3 months is 18,586,914 and the stock's 52-week low/high is $0.000000999/$0.002899999.

chart

The Pulse Beverage Corporation (PLSB)

The Green Baron, Greenbackers, Microcap MarketPlace, Wall St Insider Stocks, Ceocast News, SmallCap Network,  FreeRealTime,  PennyStocksV2, BestStocksDaily, Wall Street Resources, RedChip,  Marketbeat.com, HoleinOneStocks.net, and PennyStockClub reported previously on The Pulse Beverage Corporation (PLSB), and today we report on the Company, here at the QualityStocks Daily Newsletter.

The Pulse Beverage Corporation is the maker of Natural Cabana® Lemonades, Limeades, and Coconut Waters. It introduced Natural Cabana® Lemonade in 2012. Since that time,  it has developed a multi-national distribution system through more than 155 distributors in 49 U.S. States, Canada, Mexico, Panama, Bermuda, and Ireland.  OTCQB-listed, The Pulse Beverage Corporation is headquarterered in Northglenn, Colorado.

The Company’s aim is to be one of the market leaders in the development and marketing of nutritional/functional beverage products, which provide real health benefits to a large portion of the population and are convenient and appealing to consumers.

Pulse Beverage’s business model uses warehouse direct and key accounts. The Company has secured greater than 20,000 listings for its Lemonades and Limeades and over 5,000 listings for its Coconut Waters with regional and national grocery and convenience chain stores.

The Company offers Natural Cabana® Lemonade/Limeade in seven, low-calorie flavors.  Additionally,  Pulse  offers Natural Cabana® Coconut Water in pineapple and natural flavors.

Pulse Beverage teams up with major retailers. These retailers include Walmart, Albertsons/Safeway, Food Max, Kroger, Stater Bros, Houchens, 7-Eleven, United C-stores, Kmart, and Weis Markets. Major retailers also include King Kullen, WinCo Foods, Price Less Markets, Hy-Vee Supermarket, Gristede's Foods, Toot n Totem, and Travel America.

Recently, Pulse Beverage announced that it acquired international distribution for its Natural Cabana® Coconut Waters in the People’s Republic of China (PRC) via its new U.S. based distribution partner, Better4U Food & Beverage, Inc.

Better4U has distribution in the PRC and consumer demand for more than 15,000 cases per month worth a minimum of $450K per quarter in Net Revenues for Pulse. In this partnership, Better4U pays for the product up front. This eliminates the credit risks for Pulse.

Furthermore, in March, Pulse announced that it acquired international distribution for its Natural Cabana® Lemonades & Limeades in the Republic of China (Taiwan) via Better4U Food & Beverage. Better4U has distribution in Taiwan and consumer demand for more than 6,500 cases per month worth a minimum of $200K per quarter in additional Net Revenues for Pulse.

The Pulse Beverage Corporation (PLSB), closed Thursday's trading session at $0.0001, even for the day, on 100,000 volume with 1 trade. The average volume for the last 3 months is 216,732 and the stock's 52-week low/high is $0.000000999/$0.001.

chart

North America Frac Sand, Inc. (NAFS)

PennyStockProfessor,  SMS Penny Picks, DSR News,  eliteotc.com, Wall Street Beauties, WINNINGOTC,  BestDamnPennyStocks,  PennyPickAlerts,  TheNextBigTrade, Stock Commander, Fortune Stock Alerts, and  Penny Stock Hub reported earlier on North America Frac Sand, Inc. (NAFS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

North America Frac Sand, Inc. is a development stage company based in Saskatoon, Saskatchewan.  It owns renewable land leases with the right to extract frac sand from significant mineral deposits situated in the Province of Saskatchewan. The Company has 29,900 acres of leases and lease options, which are 30 kilometers east of Saskatoon. North America Frac Sand lists on the OTC Markets Group’s OTCQB.

North America Frac Sand acquired North America Frac Sand (CA) Ltd. and its acres of leases in 2015. In 2016, North America Frac Sand announced the completion of the due diligence obligatory preceding the decision to close on the acquisition of North America Frac Sand (CA) Ltd. (NAFS-CA).

Frac Sand is a proppant used in the oil & gas industry as part of the hydraulic fracturing process - a way to enhance flow to the wellhead. North America Frac Sand’s strategy is to achieve a major presence in the frac sand industry through developing a long term, high quality, and secure supply of frac sand for the oil & gas industry in Western Canada and the Northwestern United States.

  Frac sand must have definite characteristics. These include reaching certain levels of crush resistance, sphericity, and roundness. As a result, frac sand is a relatively rare commodity.

North America Frac Sand has established relationships with all the major well service companies. These include several large oil & gas companies. Additionally, the Company has government and municipality support.

North America Frac Sand’s short-term plan is to prove out the balance of its major resource. Its long-term plan is to begin shipments of frac sand as soon as possible.

In addition, the Company’s strategy is to develop and maximize the mineral deposit under its land and optioned leases. Its strategy is also to develop a long-term relationship with well service and oil & gas companies that center on quality service and product. Furthermore, North America Frac Sand’s strategy involves providing a year-round supply of frac sand to customers.

North America Frac Sand received its initial "Technical Report" addressing its Eagle Creek Property in Saskatchewan on May 25, 2017. The Technical Report encompasses exploration to date on a portion of the Company’s leased areas (roughly 12,100 hectares [29,900 acres]).

Recently, North America Frac Sand announced it has been in discussions with numerous Canadian publicly traded companies concerning its Eagle Ridge Property.

Mr. Joseph Kistler, North America Frac Sand President, said, "The Company has been involved with substantive discussions regarding the furtherance of the Eagle Ridge Frac Sand project and I am pleased to report that the interest has been extremely positive. It is my intention to partner with a group (in Canada near the Eagle Ridge project) that is capable to complete the drilling program so that the true value of the Company owned leases will be validated and bring value to the company's preferred and common shareholders. We plan on deciding in the very near future.”

North America Frac Sand, Inc. (NAFS), closed Thursday's trading session at $0.0085, up 102.381%, on 59,579 volume with 6 trades. The average volume for the last 3 months is 198,733 and the stock's 52-week low/high is $0.002499999/$0.034000001.

chart

The QualityStocks Company Corner

Jerrick Media Holdings, Inc. (OTC: JMDA)

The QualityStocks Daily Newsletter would like to spotlight Jerrick Media Holdings, Inc. (OTC: JMDA).

Jerrick Media Holding (OTCQB: JMDA), the parent company of the Vocal platform and the Vocal for Brands content studio, partnered with Luxury skin-care brand FOREO to increase awareness of its new products (http://nnw.fm/ZvdK9). To view the full article, visit http://nnw.fm/IN9rN

Jerrick Media Holdings, Inc. (OTC: JMDA) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Jerrick launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

 

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Jerrick provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

Upon the consummation of its anticipated listing on the Nasdaq Capital Market, Jerrick intends to change its official company name to “Creatd, Inc.,” subject to stockholder approval.

This rebranding will initiate Jerrick’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Jerrick’s potential market value via a plethora of new revenue streams.

Creatd will focus on a community of creators that number more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd will partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Jerrick was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Jerrick’s needs quickly outpaced its initial technology and product offering. In 2015, Jerrick partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Jerrick’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Jerrick’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Jerrick in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Jerrick, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During the Jerrick’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Jerrick Media Holdings, Inc. (JMDA), closed Thursday's trading session at $3.25, up 6.5574%, on 1,800 volume with 6 trades. The average volume for the last 3 months is 907 and the stock's 52-week low/high is $1.63999998/$5.00.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then help identify both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) just announced it was entering the fight against the latest scourge and is launching a new artificial intelligence platform to aid in vaccine and drug development to battle coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) (http://nnw.fm/3uS2j).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $1.47, up 6.9091%, on 239,578 volume with 808 trades. The average volume for the last 3 months is 463,622 and the stock's 52-week low/high is $1.25/$8.50.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a leading branded cannabis products company based in California, today released a letter from its Co-founder and CEO, Jake Heimark, discussing the COVID-19 pandemic and recent company developments. To view the full press release, visit http://cnw.fm/31GvN

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Thursday's trading session at $0.39, up 19.6319%, on 17,740 volume with 19 trades. The average volume for the last 3 months is 48,867 and the stock's 52-week low/high is $0.298999994/$4.49989986.

Recent News

chart

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC) was featured today in the 420 with CNW by CannabisNewsWire. The novel Coronavirus virus first appeared in Wuhan, China and in the months since it has infected over 170,000 people and left at least 7,000 dead. Naturally, countries are taking precautions, locking down cities, and restricting travel and public meetings to curb the spread of the virus. In the U.S., states and cities are slowly shutting down, with President Trump urging people to limit themselves to groups of no more than 10 people.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Thursday's trading session at $0.17, up 21.4286%, on 7,993 volume with 7 trades. The average volume for the last 3 months is 15,317 and the stock's 52-week low/high is $0.05/$3.00.

Recent News

chart

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Bolt Metals Corp. (OTCQB: PCRCF).

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE), formerly Pacific Rim Cobalt Corp., is an exploration company focused on the acquisition and development of production-grade cobalt and nickel deposits. Presently, the company is positioned to benefit from rising demand for the materials that power electric vehicles (“EVs”). To view the full article, visit http://nnw.fm/Gl3h8

Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade battery metals deposits within the Asia-Pacific region, employing a vertically integrated “minerals-to-market” strategy to leverage these assets to their fullest.

Bolt Metals Corp. is advancing its flagship, 100% controlled Cyclops Nickel-Cobalt located in Papua Province, Indonesia with a mandate to become a key contributor to Asia-Pacific’s rapidly expanding electric vehicle and battery supply chain.

The Cyclops project, uniquely positioned within the world’s largest producer of nickel and in proximity to China, the world’s largest “Gigafactory”, features near surface, strong nickel-cobalt mineralization. The property is situated in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Bolt Metals well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to nickel-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Indonesia has recently approved environmental impact studies for factories to produce battery-grade nickel chemicals in Morowali. The approval will allow investors, such as China’s stainless steel giant Tsingshan Group, to continue the construction of their high-pressure acid leaching plants in Morowali, Central Sulawesi.

Ranjeet Sundher, chief executive officer of Bolt Metals, said: “Indonesia continues to make significant strategic decisions, and this latest announcement represents an important step in Bolt Metals’s efforts to benefit from Indonesia’s rapid development as a leading market for all stages of the EV supply chain. With offices in Vancouver, Shanghai and Jakarta, Bolt Metals is well positioned to leverage Asia’s global dominance in the battery manufacturing sector.”

Indonesia’s commitment extends to the very top of government, with Joko Widodo – Indonesia’s President – stating in September 2019 that “for nickel, we want raw materials to be processed in Indonesia. We want added values”. This supports previous pronouncements from key officials, including Indonesian Maritime Minister, Luhut Pandjaitan who remarked that Indonesia will “become the main player in lithium batteries” and that it will “control the world market”.

The country, which is the world’s top nickel ore exporter, has stopped export of unprocessed nickel ore to support this plan.

During 2019 the Company carried out an extensive exploration and development program on Cyclops and achieved successful nickel results with its drilling and bench-scale scoping tests for processing of materials.

Drilling identified significant horizons of nickel mineralization and bench-scale scoping tests returned positive results for processing of this nickel rich material.

The recovery percentages form the bench-scale test program are set out below (for further information, please refer to the Company’s press release of October 28, 2019):

Sample Nickel (%) Cobalt (%) Iron (%)
Limonite 99.26 98.82 97.77
Low Iron Transition 99.75 97.03 99.22
Saprolite 99.77 >99.9 99.74

 

Selected elevated nickel drill results are provided below from the Company’s shallow drilling program (for further information, please refer to the Company’s press releases of March 5, April 1, April 23, June 13, June 20 and September 10, 2019):

Intersection length (metres from surface) Nickel (%) Cobalt (%)
7.0 2.15% 0.03%
4.0 1.96% 0.04%
2.0 2.00% 0.01%
2.0 1.91% 0.05%

 

2020 will see continued and consistent development in Pacific Rim Cobalt’s strategy as the company continues to set ambitious milestones with the goal of becoming a leading international player in the EV battery metal sector and creating significant long-term shareholder value.

This includes preparations to commission and operate the company’s pilot plant in Canada, which will contain an integrated circuit to produce high-purity nickel and cobalt strip solutions to develop battery-grade nickel and cobalt.

The results of the pilot plant will then be used to establish the design criteria for the subsequent demonstration plant in Indonesia, which will produce nickel and cobalt products suitable to meet market specifications. As well as demonstrating Pacific Rim Cobalt’s ability to produce a product within market specifications, this will also be used to establish the design criteria for the company’s commercial-scale plant.

Pacific Rim Cobalt’s world-class management team includes Ranjeet Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Bolt Metals Corp. (OTCQB: PCRCF), closed Thursday's trading session at $0.123, up 3.3613%, on 50,645 volume with 21 trades. The average volume for the last 3 months is 49,662 and the stock's 52-week low/high is $0.079999998/$0.355599999.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint (OTCQB: SING) today announced the launch of its new corporate website that highlights its core business entities and includes an updated corporate video that provides an overview and outlook for 2020. To view the full press release, visit http://cnw.fm/LGP7u

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Thursday's trading session at $0.0054, up 15.3846%, on 8,601,771 volume with 182 trades. The average volume for the last 3 months is 4,524,144 and the stock's 52-week low/high is $0.004/$0.021999999.

Recent News

chart

Champignon Brands Inc. (CSE: SHRM)

The QualityStocks Daily Newsletter would like to spotlight Champignon Brands Inc. (CSE: SHRM).

Champignon Brands Inc. (CSE: SHRM), a wellness company specializing in the formulation and distribution of a group of artisanal-mushroom health supplements, recently began trading on the Canadian Securities Exchange (CSE). In February 2020, SHRM successfully completed an initial public offering (IPO) through lead agent PI Financial Corp. Additionally, Champignon Brands will look to secure a listing on the Frankfurt Stock Exchange and a quotation on the OTC Marketplace in the United States as soon as is feasible (http://cnw.fm/LP3Xt). Also today, CannabisNewsWire released a report on the company detailing how SHRM has announced the expansion of its vertically integrated, alternative medicine product portfolio with the addition of new proprietary intellectual property (“IP”). To view the full press release, visit http://cnw.fm/ORi8l

Champignon Brands Inc. (CSE: SHRM) is a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements. Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon’s expanding portfolio is crafted with the health-conscious consumer in mind.

Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

Brands

Champignon’s mushroom-derived consumer packaged goods (CPGs) portfolio includes its flagship brand, Vitality Superteas. Each carefully curated Vitality Supertea formulation was developed with the intent of helping individuals enhance and enrich their wellbeing one cup of mushroom-infused tea at a time.

Also in the portfolio are Nourish Force Supertea, a blend of Reishi Ryobus Tea Mix; Mighty Recharge Supertea, created with Lions Mane Tropical Green Ginseng Tea Mix; and Brain Enhance Supertea, a blend of Cordycep Hibiscus and Berries Tea Mix – all of which are formulated with organic ingredients and chosen for their ability to provide unique health and performance benefits.

Champignon’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom vertical space with a selection of mushroom-infused teas and accessories.

Functional Mushroom Market

Demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024 (ResearchandMarkets), with Europe seen as the fastest growth leader.

According to the market study, in highest demand are products infused with Reishi – a traditional Chinese medicine also known as the “Elixer of Life” and “Mushroom of Immortality – Lions Mane and Cordyceps, followed by other types of medicinal mushrooms.

Advances in Legalization

Legalization of psychedelics for use in medicine is gaining momentum across the United States. Denver, Colorado, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for legalization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7 million people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
A renaissance in alternative medicines is emerging, and Champignon has set in motion its strategy to become a key player.

2020 Stealth IP Strategy

Champignon plans to biosynthesize psilocybin within the first three months of conducting laboratory experiments, with the objective of achieving optimized and scaled production of pharmaceutical-grade psilocybin for deployment in clinical settings. This strategy includes:

  • Alternative medicine (psilocybin) IP aggregation
  • Development of cGMP formulations of bioactive compounds extracted from plants and Fungi
  • Drafting of benchmark SOPs (Standard Operating Procedures)
  • Patient aggregation, focusing on veterans

Defining a New Asset Class: Psychedelic-Inspired Medicines

In the third quarter of 2020, Champignon – through clinical trials, a compelling IP portfolio and clinical pipeline and drug development platform – plans to advance its pursuit of treatments underpinned by psychedelic substances. This strategy is broken down into two ties:

  • Non-Hallucinogenic Medicines
    • Microdosing Psilocybin/LSD
    • MDMA, commonly known as ecstasy
  • Hallucinogenic Medicines
    • Psilocybin high dose
    • LSD high dose

Partnerships

Companies worldwide are beginning to incorporate functional mushrooms into their product offerings, taking advantage of growing consumer awareness of known health benefits of the ingredients found in mushrooms.

Champignon in November 2019 entered into a distribution partnership with Eurolife Brands Inc. (CSE: EURO), a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics. Under the agreement, Champignon’s branded products are integrated into Eurolife’s e-commerce platform, along with potential distribution opportunities in select brick-and-mortar retail locations in Europe.

Champignon also has an R&D/production formulation agreement with Drip Coffee Social Ltd., located in Nanaimo, British Columbia, which calls for the infusion of Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.

Leadership

Gareth Birdsall, CEO, Corporate Secretary and Director
Gareth Birdsall has more than seven years of experience working in diverse agricultural roles such as the cultivation of various fungi, in particular Cordycepes, Reishi, Lions Mane and Chaga. He is an attendee of the British Columbia Institute of Technology, studying marketing management and finance.

Steven Brohman, CPA, CFO
Steven Brohman has more than 10 years of experience working in a variety of roles with public and private companies. He has had extensive training in the audit of publicly traded companies on the TXS, TSX Venture Exchange and OTC markets, and serves as CFO and director of various public and private companies. Brohman has a bachelor’s degree of business administration and obtained his Chartered Professional Accountant designation.

Jerry Habuda, Director
Jerry Habuda brings to Champignon over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

Champignon Brands Inc. (CSE: SHRM), closed Thursday's trading session at $0.33, even for the day, on 890,559 volume with 112 trades. The 52-week low/high is $0.30/$0.33.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

A fintech enterprise, ChineseInvestors.com Inc. (OTCQB: CIIX) is focusing on its original mission of providing financial information and services to the larger Chinese community in the United States and globally. CIIX has become a leading financial-information website (in Chinese language character sets) for Chinese-speaking investors in the United States and China and continues to pursue new areas for growth in other industries as well (http://cnw.fm/2Rinf).

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Thursday's trading session at $0.102, even for the day, on 85,100 volume with 28 trades. The average volume for the last 3 months is 58,824 and the stock's 52-week low/high is $0.100000001/$0.50999999.

Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and healthcare platform, recently announced its uplisting to the Nasdaq Capital Market and rang the opening bell on Friday, Feb. 28, 2020. To view the full article, visit http://nnw.fm/HQog9

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Thursday's trading session at $4.36, off by 6.2366%, on 756 volume with 28 trades. The average volume for the last 3 months is 37,158 and the stock's 52-week low/high is $2.0999999/$10.5600004.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced the initiation of a program, in collaboration with leading laboratories in Canada and the USA, to analyze the benefits of Lexaria's DehydraTECH(TM) drug delivery platform for improving delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. To view the full press release, visit http://cnw.fm/H8WgV

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Thursday's trading session at $0.299, up 24.5833%, on 488,486 volume with 284 trades. The average volume for the last 3 months is 106,750 and the stock's 52-week low/high is $0.229499995/$1.34000003.

Recent News

chart

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (OTCQB: NUGS).

Cannabis Strategic Ventures (OTCQB: NUGS), an emerging leader in the U.S. and California cannabis marketplaces, today announced another milestone at the company’s licensed cultivation operation in northern California, NUGS Farm North. To view the full press release, visit http://cnw.fm/gmFo0

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (OTCQB: NUGS), closed Thursday's trading session at $0.045, up 7.1429%, on 537,976 volume with 105 trades. The average volume for the last 3 months is 1,333,891 and the stock's 52-week low/high is $0.025499999/$1.48000001.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) announced today that Peter Horvath is stepping down as Chief Executive Officer and as a member of the Board of Directors effective today.  Mr. Horvath has served as CEO of the Company since January 2019 and as a member of the Company's Board of Directors since July 2018.  Randy Whitaker, the Company's current Chief Operating Officer will take over as interim Chief Executive Officer, effective immediately.  Mr. Whitaker has served as the Company's Chief Operating Officer since February 2019.  The vacancy on the Company's Board of Directors will be filled in due course.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Thursday's trading session at $0.0695, off by 2.5245%, on 1,405,450 volume with 506 trades. The average volume for the last 3 months is 647,157 and the stock's 52-week low/high is $0.054000001/$4.48999977.

Recent News

chart

Xalles Holdings Inc. (OTC: XALL)

The QualityStocks Daily Newsletter would like to spotlight Xalles Holdings Inc. (OTC: XALL).

Xalles Holdings Inc. (OTC: XALL), a fintech holding company leveraging blockchain technology for financial reconciliation and payment auditing solutions, today announced its execution of a Share Purchase Agreement to acquire 100% of MinervaWorks Holdings, Inc., an Atlanta based technology company. To view the full press release, visit http://ccw.fm/Cdm74

Xalles Holdings Inc. (OTC: XALL) is a fintech holding company leveraging blockchain and other technologies for e-commerce, payments, financial reconciliation, and payment auditing solutions. The company actively seeks acquisition targets with strong management teams and business models, large total attainable markets, and lucrative exit opportunities in which to invest and accelerate growth.

Operations

The common element to all acquired entities and projects is a business model that involves setting up a payment or financial transaction “toll gate,” thereby creating a recurring revenue stream.

Xalles’ business plan focuses on consumer, business and government-oriented payment and financial reconciliation transactions. Combining the blockchain decentralized financial ledger platform with the company’s existing X2X transaction reconciliation system design, Xalles is building technology that supports payment audits, exchanges, and new business models and opportunities worldwide. Xalles will launch new services card and mobile payment and rewards systems, and will expand the technology offerings for referral marketing and e-commerce engines.

Subsidiaries
(all current subsidiaries are wholly owned)

  • Xalles Holdings
    Raise capital for fintech accelerator program acquisitions, provide management, administrative, finance and marketing support to all subsidiary companies
  • Xalles Capital
    Management support of investment consortiums, direct investment into funds or projects, and management of investments
  • Xalles Limited
    Design and market new X2X solutions; acquire U.S Government transportation post-payment audit business through GSA schedule and expand to non-transportation payment auditing
  • Xalles Technology
    Technical development of the X2X blockchain systems
  • Xalles Financial Services
    Consumer and small business financial service offerings
  • Co-Owners Rewards
    Stock-based rewards system for payments cards and financial services
  • Amazing Living Enterprises
    Affiliate program and e-commerce platform for enhancing financial lives
  • Global Savings Network
    Not-for-profit fundraising system with consumer discounts at local merchants

X2X Solutions

Xalles provides payment and financial transaction management solutions through the company’s proprietary blockchain-based X2X technology. The X2X solution includes the Investment and Financing System (IFS), which supports complex investment structures, assists international investment consortia, and provides links to Xalles’ Financial Transaction Reconciliation (FTR) solution. FTR supports complex financial ecosystems, making it easier for parties to exchange products, services, grants and government incentives, and assists “Exchange Managers” with liquidity and auditability. X2X also supports the Xalles pre- and post-payment auditing services.

Plans for 2020

  • Xalles expects to announce new acquisitions of fintech growth firms.
  • The company’s strategy for 2020 includes revamping its consumer Commerce platform, to bring in the best elements of local and online shopping with payment tools and a unique rewards program.
  • Xalles Financial Services expects to expand its cryptocurrency related service offerings through partnerships, acquisitions and organic growth
  • The Blockchain based X2X system will continue to be enhanced to deliver new financial reconciliation services to large enterprises and governments.

Xalles Holdings Inc. (OTC: XALL), closed Thursday's trading session at $0.0009, off by 10.00%, on 8,170,000 volume with 38 trades. The average volume for the last 3 months is 2,510,736 and the stock's 52-week low/high is $0.000699999/$0.021029999.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $0.135, up 28.4491%, on 734,162 volume with 329 trades. The average volume for the last 3 months is 507,804 and the stock's 52-week low/high is $0.101000003/$1.75.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.